Ossiam Has $28.59 Million Stake in Danaher Corporation $DHR

Ossiam increased its stake in Danaher Corporation (NYSE:DHR) by 716.7% in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 144,744 shares of the conglomerate’s stock after purchasing an additional 127,022 shares during the quarter. Ossiam’s holdings in Danaher were worth $28,593,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. White Pine Capital LLC boosted its holdings in shares of Danaher by 1.4% during the 2nd quarter. White Pine Capital LLC now owns 3,494 shares of the conglomerate’s stock worth $690,000 after buying an additional 49 shares during the period. Boyd Watterson Asset Management LLC OH lifted its position in Danaher by 2.1% during the 2nd quarter. Boyd Watterson Asset Management LLC OH now owns 2,524 shares of the conglomerate’s stock worth $499,000 after acquiring an additional 51 shares during the last quarter. Worth Financial Advisory Group LLC boosted its holdings in Danaher by 4.6% during the second quarter. Worth Financial Advisory Group LLC now owns 1,195 shares of the conglomerate’s stock valued at $236,000 after acquiring an additional 53 shares during the period. Bruce G. Allen Investments LLC grew its position in shares of Danaher by 13.1% in the second quarter. Bruce G. Allen Investments LLC now owns 467 shares of the conglomerate’s stock valued at $92,000 after purchasing an additional 54 shares during the last quarter. Finally, Texas Bank & Trust Co increased its stake in shares of Danaher by 1.6% in the second quarter. Texas Bank & Trust Co now owns 3,567 shares of the conglomerate’s stock worth $705,000 after purchasing an additional 55 shares during the period. Institutional investors and hedge funds own 79.05% of the company’s stock.

Insider Activity at Danaher

In other news, SVP Brian W. Ellis sold 21,776 shares of the business’s stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $219.23, for a total value of $4,773,952.48. Following the sale, the senior vice president owned 14,553 shares in the company, valued at approximately $3,190,454.19. The trade was a 59.94% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Georgeann Couchara sold 5,174 shares of the company’s stock in a transaction dated Monday, November 10th. The stock was sold at an average price of $210.42, for a total transaction of $1,088,713.08. Following the completion of the sale, the senior vice president directly owned 2,625 shares in the company, valued at approximately $552,352.50. The trade was a 66.34% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 30,248 shares of company stock valued at $6,609,663 in the last 90 days. 11.20% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

DHR has been the topic of a number of research analyst reports. Barclays raised their target price on Danaher from $225.00 to $250.00 and gave the company an “overweight” rating in a report on Wednesday, October 22nd. HSBC increased their price target on shares of Danaher from $255.00 to $270.00 and gave the company a “buy” rating in a report on Monday, December 1st. JPMorgan Chase & Co. boosted their price objective on shares of Danaher from $260.00 to $270.00 and gave the stock an “overweight” rating in a report on Wednesday, October 22nd. Wall Street Zen upgraded shares of Danaher from a “hold” rating to a “buy” rating in a research note on Saturday, November 22nd. Finally, Rothschild Redb downgraded Danaher from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 8th. Twenty analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $245.75.

Danaher Trading Down 0.4%

Shares of DHR stock opened at $226.20 on Monday. The firm has a fifty day moving average of $216.22 and a 200-day moving average of $204.48. The stock has a market cap of $159.78 billion, a price-to-earnings ratio of 46.64, a P/E/G ratio of 4.39 and a beta of 0.89. Danaher Corporation has a 52-week low of $171.00 and a 52-week high of $258.23. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.10 and a current ratio of 1.52.

Danaher (NYSE:DHR) last posted its earnings results on Monday, October 20th. The conglomerate reported $1.89 earnings per share for the quarter, beating analysts’ consensus estimates of $1.72 by $0.17. Danaher had a net margin of 14.44% and a return on equity of 10.92%. The business had revenue of $6.05 billion for the quarter, compared to analysts’ expectations of $6 billion. During the same quarter in the previous year, the firm posted $1.71 earnings per share. The firm’s revenue for the quarter was up 4.4% on a year-over-year basis. On average, equities research analysts forecast that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, October 31st. Investors of record on Friday, September 26th were given a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a dividend yield of 0.6%. The ex-dividend date was Friday, September 26th. Danaher’s dividend payout ratio (DPR) is 26.39%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.